Michael Koval, MD
Ophthalmology · Farmington, CTNPI 1710246772
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,500 of the $34,696 with a category attached, or 79.3%. AbbVie accounts for 98.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $14,782 and has fallen 66.2% since, to $5,003 in 2025. Among ophthalmology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $456.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$34K
- Alcon$225
- Aerie Pharmaceuticals, Inc.$111
- Sight Sciences, Inc.$73
- Carl Zeiss Meditec AG$39
- Johnson & Johnson Surgical Vision, Inc.$15
- plus $13 from 1 others
What the payments were for
- Speaking & faculty fees$27,50079%
- Travel & lodging$4,48613%
- Food & beverage$2,5697%
- Education$130%
- Gifts$1290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 64 | $34,221 |
| Alcon | 3 | $225 |
| Aerie Pharmaceuticals, Inc. | 1 | $111 |
| Sight Sciences, Inc. | 4 | $73 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $15 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$32,388
- Clareon PanOptix Pro$122
- Rhopressa$111
- Rocklatan$111
- XEN$104
How this compares
$34,696 in reported general payments places this provider in the 95th percentile of 279 ophthalmology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 617 | $410,019 |
| RhopressaNetarsudil Mesylate | 256 | $148,521 |
| CombiganBrimonidine Tartrate/Timolol | 142 | $76,992 |
| VyzultaLatanoprostene Bunod | 99 | $60,322 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 378 | $59,239 |
| RestasisCyclosporine | 47 | $57,516 |
| Alphagan PBrimonidine Tartrate | 106 | $54,763 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 167 | $50,847 |
| Brinzolamide | 227 | $45,060 |
| RocklatanNetarsudil Mesylat/Latanoprost | 80 | $44,133 |
| Travoprost | 219 | $38,115 |
| Cyclosporine | 69 | $33,867 |
| XiidraLifitegrast | 15 | $29,481 |
| Travatan ZTravoprost | 41 | $28,478 |
| Prednisolone Acetate | 764 | $27,400 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $34,221 | $599,290912 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $111 | $192,654336 claims |
| AlconSimbrinza, Azopt | $225 | $65,544196 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $13 | $6,94728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 279 ophthalmology providers in Connecticut.
Other ophthalmology in Farmington
- Madina FalconeFarmington$23K
- John HuangHartford$267K
- Amir CohenNew Haven$266K
- James MurphyHamden$176K
- James TalbotNew Canaan$47K
- Paul KangNew Haven$40K
- Anish ShahNorwich$38K
- Scott SpectorNorwalk$23K
- Flora LevinBridgeport$19K
- Lorenzo CervantesShelton$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.